Compare Adaptive Biotechnologies Corp (ADPT) vs Live Nation Entertainment, Inc. (LYV) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Live Nation Entertainment, Inc. — how do they compare? Adaptive Biotechnologies Corp trades at $20.24 (market cap $3.33B), while Live Nation Entertainment, Inc. trades at $182.19 (market cap $42.80B). The key difference: Live Nation Entertainment, Inc. is far larger — about 12.9× Adaptive Biotechnologies Corp's market cap, and Live Nation Entertainment, Inc. is trading nearer its 52-week high, Adaptive Biotechnologies Corp nearer its low. Which is the better fit depends on your goals.
| ADPT | LYV | |
|---|---|---|
Market Cap | $3.33B | $42.80B |
Sector | Health | Industrials |
52-Week High | $22.37 | $186.59 |
52-Week Low | $10.24 | $125.61 |
Enterprise Value | $3.19B | $44.31B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Live Nation (LYV) trades at $183.92, down 1.43% with a bullish technical signal despite recent earnings misses. The stock shows strong analyst support with 88.6% buy ratings and a $194 consensus target. Revenue growth remains solid at $25.2B for 2025, though profitability metrics are weak with a 0.33% net margin and negative ROE. Recent news highlights strong concert demand and strategic initiatives.
Outlook remains positive driven by live event recovery and ticketing dominance, but elevated valuation ratios and profitability challenges present risks. The stock faces headwinds from legal expenses and consumer spending pressures, requiring careful monitoring of execution against growth expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Live Nation Entertainment, Inc.
Live Nation is the largest live entertainment firm in the world with over 570 million fans served in 44 countries in 2018 by the company's concert and ticketing platforms. Via either owning, operating, or holding exclusive booking rights, Live Nation controls over 235 venues including the House of Blues, the Hollywood Palladium, and Spark Arena in New Zealand. Live Nation also owns one of the largest ticketing services, Ticketmaster, which sold over 480 million tickets for over 12,000 clients in 2018. The firm's artist management agencies have over 400 clients. This large live entertainment footprint helped Live Nation become one of the largest advertising and sponsorship platforms aimed at music fans. Liberty Media owns 33% of Live Nation, held under its SiriusXM tracking stock.
Read more on LYV →
